Short answer
Axsome Therapeutics, Inc. (AXSM) filed an 8-K current report with the SEC on July 15, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). FDA acceptance of AXS-12 NDA for cataplexy in narcolepsy advances Axsome’s regulatory pipeline.
Axsome Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- FDA acceptance of AXS-12 NDA for cataplexy in narcolepsy advances Axsome’s regulatory pipeline
- Filing acceptance triggers FDA review, but does not indicate approval or commercial availability
- AXS-12 could expand Axsome’s addressable narcolepsy treatment portfolio if approved
Item EX-99.1 · Exhibit EX-99.1
- FDA accepted AXS-12 NDA for cataplexy in narcolepsy, advancing the candidate into regulatory review
- PDUFA target action date: May 1, 2027, establishing the next major catalyst
- FDA does not currently plan an advisory committee, potentially simplifying the review path
- AXS-12 has Orphan Drug Designation but remains unapproved, leaving regulatory and commercialization risk
- Cataplexy affects an estimated 70% of narcolepsy patients, supporting a substantial addressable indication
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Axsome Therapeutics, Inc. 8-K filings
Get the next AXSM 8-K as it lands
Follow AXSM for push alerts, or ask the research agent what this filing means.